americanpharmaceuticalreviewNovember 18, 2020
Tag: Immutep , IMP701 , LAG525 , LAG-3
Immutep has announced the grant of patent no. 2015229103 entitled “Antibody molecules to LAG-3 and uses thereof” by the Australian Patent Office.
This new Australian patent builds on the corresponding US patents announced in March 2018 and July 2020, a European patent announced in November 2019, and a Japanese patent announced in September 2019. The Australian patent is directed to LAG525, pharmaceutical compositions comprising LAG525, the use of LAG525 in the treatment of cancer or infectious disease, nucleic acid molecules that code for the LAG525 antibody, and to various combination treatments comprising LAG525 and a second therapeutic agent or procedure.
LAG525 is a humanized form of Immutep’s IMP701 antibody which is out-licensed to Novartis AG.
The patent is co-owned by Novartis AG and Immutep S.A.S. and will expire on 13 March 2035.
IMP701 is a therapeutic antibody originally developed by Immutep to target LAG-3. This antagonist antibody plays a role in controlling the signaling pathways in both effector T cells and regulatory T cells (Treg). The antibody works to both activate effector T cells (by blocking inhibitory signals that would otherwise switch them off) and at the same time inhibit Treg function that normally prevents T cells from responding to antigen stimulation. The antibody therefore removes two brakes that prevent the immune system from responding to and killing cancer cells. In contrast, some other checkpoint antibodies in development target only the effector T cell pathway and don’t address the Treg pathway.
LAG525, a humanized form of IMP701 is currently being evaluated in five Phase I and/or Phase II clinical trials in combination with Novartis’ PD1 inhibitor spartalizumab for the treatment of various cancers. Novartis has full responsibility for the continued development of the antibody program. Immutep is eligible to receive development-based milestone payments and royalties on sales following commercialization of the antibody.
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: